et=utf-8" http-equiv=Content-Type> 
欢迎光临天津津南无痛人流多少钱 肿瘤治疗咨询热线:0551-4396116
天津津南无痛人流医院_肿瘤治疗生物治疗中心 天津津南无痛人流多少钱荣誉资质
卵巢囊肿 药物流产 人流术前指导 人流术后保健 人流避孕预防 宫外孕 计划生育 无痛人流 早孕检查 人流准备 人流多少钱 子宫颈疾病 宫颈糜烂 宫颈肥大 宫颈炎 宫颈息肉 妇科中心 阴道疾病 白带异常 外阴炎 月经不调 不孕不育 输卵管堵塞 内分泌失调性 宫颈性不孕 不孕其他 不孕 生殖整形 处女膜修复 阴道紧缩小 阴道脱垂
您现在的位置(天津津南无痛人流医院|):  天津津南区人流医院 > 妇科肿瘤 > 宫外孕 > 宫外孕治疗 >

BRCA突变的宫外孕预后并不差

摘要:有BRCA突变者,一生出现宫外孕的可能性高于没有突变者,但预后并不一定差。如此,检测BRCA突变并据此预防性切除乳房可能有更多争议。

Breast Cancer Prognosis in BRCA1 and BRCA2 Mutation Carriers: An International Perspective Breast Cancer Family Registry Population-Based Cohort Study

Goodwin PJ, Phillips KA, West DW, et al

J Clin Oncol. 2012;30:19-26

Summary

Using survival data from a population of 3220 breast cancer patients in Canada, the United States, and Australia, researchers sought to explore the outcomes of women with breast cancer and known BRCA mutations vs individuals with sporadic disease (ie, no BRCA mutation). Patients had a median age of 45.3 years; 93 patients had a documented BRCA1 mutation, 71 patients had a documented BRCA2 mutation, and 1 patient had both.

After a mean follow-up of nearly 8 years, univariate and multivariate analyses showed no difference in the risk for distant recurrence or death between patients with BRCA1 mutations and those with sporadic breast cancer.

Of note, univariate analysis showed that the risk for both recurrence (hazard ratio, 1.63; P = .04) and death (hazard ratio 1.81; P = .01) was greater for BRCA2 carriers vs those with sporadic disease, although this difference was not observed in a multivariate analysis. Rather, the multivariate analysis suggested that the differences observed between the BRCA2 carriers and those with sporadic breast cancer were related to the presence of more adverse clinical features (eg, greater nodal involvement, higher tumor grade) in the mutation-positive group.

Viewpoint

It is well-established that women with mutations in BRCA1 or BRCA2 have an increased lifetime risk for breast cancer and, to a lesser degree, ovarian cancer. In addition, considerable research has demonstrated the utility of prophylactic surgery in reducing that risk.[1]

However, although there is a fair amount of data in the medical literature regarding the potential favorable effects of BRCA mutations in women diagnosed with ovarian cancer (possibly due to enhanced sensitivity of the cancer to platinum agents),[2] there is less information on the specific influence of BRCA status on outcome (ie, risk for recurrence and death) in breast cancer.

The current report is important and generally reassuring to women with documented BRCA1 mutations who are found to have breast cancer. The data show that, as a group, this population does not have a worse outcome than individuals with sporadic disease.

However, the data also suggest that a BRCA2 mutation may be associated with less favorable clinical features that result in higher risk for both recurrence and death.

It is important to note the limited sample size on which the conclusions regarding BRCA2 and its association with adverse prognostic factors have been made. It is also relevant to acknowledge that this analysis suggests that outcome is influenced more by well-established clinical factors (eg, stage, grade, hormonal status, number of lymph nodes involved) rather than by the presence or absence of the BRCA mutation. Additional reports from other groups of investigators with access to BRCA mutation status and data on long-term survival outcomes will be important to confirm or refute the findings in this report.

(责任编辑:admin)
癌症肿瘤生物治疗 —— 肿瘤治疗最有效突破 HYK免疫细胞治疗技术
  • HYK免疫细胞治疗是应用生物技术,调节和增强肿瘤患者机体的免疫防御机制,杀伤或抑制肿瘤细胞生长,不但对肿瘤细胞,对肿瘤干细胞和...[查看详细]
  • 免疫细胞治疗-晚期肿瘤患者生存期延长1-3倍
  • 配合生物治疗的患者平均生存期可延长1到3倍,治疗总体有效率可提高约15%...[查看详细]
  • “带瘤生存”不是梦,免疫细胞治疗让癌症成为慢性病
  • 免疫细胞治疗:维持宿主与肿瘤之间的平衡,当我们的免疫系统大幅度下降时,就不清除... [查看详细]
Tag: 宫外孕 宫外孕治疗
keywords:宫外孕,宫外孕治疗
刘爱国 院长
梅蔚德 教授
姜永健 教授
洪孝英 教授
许伯寿 教授
文件类型: 宫外孕 宫外孕治疗